Expert Content Library Published Articles

Published Articles

• August 25, 2021

  Single-Dose Drug Delivery Fill-Finish Facility that is Scalable, Flexible, and able to Deliver up to 45M Units Per Month Delivered within an Accelerated Timeline of Fewer Than 7 Months
  Part 3 of Pharmaceutical Technology Post-Webinar Series

  ApiJect committed to creating emergency temporary fill-finish capacity for up to 45M doses a month of a candidate COVID-19 vaccine on BFS lines by the end of 2020. All of these BFS-packaged doses could then be used, if necessary, in ApiJect Prefilled Injectors for scalable, single-dose delivery.

  READ HERE
• August 24, 2021

  Solving Drug Challenges with Innovation, BFS, and a Technology Platform to Create Drug
  Delivery Systems
  Part 2 of Pharmaceutical Technology Post-Webinar Series

  Learn how ApiJect built its Technology Platform around BFS to create innovative drug delivery systems for the prefilled syringe market and other sterile liquid pharmaceutical delivery formats.

  READ HERE
• August 23, 2021

  BFS and Prefilled Syringes: A Solution for Complex Formulations
  Part 1 of Pharmaceutical Technology Post-Webinar Series

  Many countries, including the US, lack the necessary surge capacity to reliably fill-finish and deliver billions of incremental doses of injectable drugs and vaccines during bio-emergencies.

  READ HERE
• May 9, 2021

  Special Feature: PFS & Parenteral Manufacturing: How COVID-19 Changed the Market
  Drug Development & Delivery, Issue: May 2021

  Worldwide, the parenteral market is seeing greater emphasis on patient safety. This is driving a strong trend to­ward unit-dose formats, including Blow-Fill-Seal pre­filled syringe, which are now the fastest-growing format for injectables.

  READ HERE